A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
The primary purpose of this study is to determine the safety and tolerability of AB801, and to understand the pharmacokinetic (PK) profile of AB801 when taken as a capsule and tablet in healthy volunteers.
Cancer
DRUG: AB801|DRUG: Placebo
Number of Participants with Adverse Events (AEs), Up to 30 days|Area Under the Plasma Drug Concentration-Time Curve (AUC), Predose, Up to 120 hours postdose|Maximum Concentration (Cmax) in Plasma, Predose, Up to 120 hours postdose|Time to Maximum Concentration (Tmax) in Plasma, Predose, Up to 120 hours postdose|Half-Life Time (t1/2), Predose, Up to 120 hours postdose
Change from Baseline in Holter Electrocardiogram Monitoring Scale, Predose up to 25 hours postdose
The primary purpose of this study is to determine the safety and tolerability of AB801, and to understand the pharmacokinetic (PK) profile of AB801 when taken as a capsule and tablet in healthy volunteers.